Results 61 to 70 of about 785,489 (353)

Autophagy processes are dependent on EGF receptor signaling [PDF]

, 2018
Autophagy is a not well-understood conserved mechanism activated during nutritional deprivation in order to maintain cellular homeostasis. In the present study, we investigated the correlations between autophagy, apoptosis and the MAPK pathways in ...
Capodifoglio, Sabrina, Caruso, Marika, Conti, Pio, Flati, Vincenzo, Iuliis, Vincenzo De, Lanuti, Paola, Marino, Antonio, Marricareda, Valeria, Martinotti, Stefano, Marynuk, Anna, Talora, Claudio, Toniato, Elena, Ursi, Sebastiano   +12 more
core   +1 more source

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

Clinical Cancer Research, 2013
Purpose: All patients with EGF receptor (EGFR)–mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large ...
H. Yu, M. Arcila, N. Rekhtman, C. Sima, M. Zakowski, W. Pao, M. Kris, V. Miller, M. Ladanyi, Gregory Riely   +9 more
semanticscholar   +1 more source

Perspectives on Drug Product Design Among Patients with Lung Cancer in the United Kingdom

Pulmonary Therapy
Introduction The use of oral anticancer medications has become more prevalent in cancer therapy. This is particularly the case in the management of advanced non-small cell lung cancer (NSCLC).
Joshua R. Coulter, Louis Edward Baig, Amy Antipas, Debra Montague, Angela Terry, Sally-Anne Dews, Michaela Ogden-Barker, Colm Doody, Brett Hauber   +8 more
doaj   +1 more source

A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells

OncoImmunology, 2018
Though Vγ9Vδ2-T cells constitute only a small fraction of the total T cell population in human peripheral blood, they play a vital role in tumor defense and are therefore of major interest to explore for cancer immunotherapy.
Renée C. G. de Bruin, John P. Veluchamy, Sinéad M. Lougheed, Famke L. Schneiders, Silvia Lopez-Lastra, Roeland Lameris, Anita G. Stam, Zsolt Sebestyen, Jürgen Kuball, Carla F. M. Molthoff, Erik Hooijberg, Rob C. Roovers, James P. Di Santo, Paul M. P. van Bergen en Henegouwen, Henk M. W. Verheul, Tanja D. de Gruijl, Hans J. van der Vliet   +16 more
doaj   +1 more source

The Relationship between IGF Pathway and Acquired Resistance to Tyrosine Kinase Inhibitors in Cancer Therapy

Frontiers in Bioscience-Landmark, 2023
The tyrosine kinase signaling pathway is an important pathway for cell signal transduction, and is involved in regulating cell proliferation, cell cycle, apoptosis and other essential biological functions.
Yanjing Peng, Jinjing Tan
doaj   +1 more source

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. [PDF]

, 2019
PurposeTo date, evidence for tissue epidermal growth factor receptor (EGFR) overexpression as a biomarker for anti-EGFR therapies has been weak. We investigated the genomic landscape of EGFR amplification in blood-derived cell-free tumor DNA (cfDNA ...
Fanta, Paul T, Goodman, Aaron, Kato, Shumei, Kurzrock, Razelle, Lanman, Richard B, Lee, Suzanna, Lippman, Scott M, Mareboina, Manvita, Okamura, Ryosuke, Patel, Sandip P, Raymond, Victoria M, Schwab, Richard B, Sicklick, Jason K, Vu, Peter   +13 more
core   +1 more source

GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity. [PDF]

, 2016
Abnormal activation of the epidermal growth factor receptor (EGFR) due to a deletion of exons 2-7 of EGFR (EGFRvIII) is a common alteration in glioblastoma (GBM). While this alteration can drive gliomagenesis, tumors harboring EGFRvIII are heterogeneous.
David James, C, Engler, Jane R, Ewald, Andrew J, Gong, Henry, Huillard, Emmanuelle, Koshkakaryan, Gayane, Lindberg, Olle R, McKinney, Andrew, Molinaro, Annette M, Phillips, Joanna J, Robinson, Aaron E, Shieh, Joseph T   +11 more
core   +1 more source

Multi‐omic profiling of squamous cell lung cancer identifies metabolites and related genes associated with squamous cell carcinoma

Molecular Oncology, EarlyView.
Using multi‐omic characterization, we aimed to identify key regulators specific to squamous cell lung carcinoma (SqCC). SqCC‐specific differentially expressed genes were integrated with metabolics data. High expression of the creatine transporter SLC6A8, along with elevated creatine levels, appeared to be a distinct metabolic feature of SqCC.
Johan Staaf, Daniel Ehinger, Hans Brunnström, Mats Jönsson, Frida Rosengren, Marija Kotevska, Anna Karlsson, Mattias Aine, Christian Frezza, Maria Planck, Elsa Arbajian   +10 more
wiley   +1 more source

A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors

Molecular & Cellular Oncology, 2020
Previous analysis of Phase 3 clinical trial data for colorectal cancer patients treated with cetuximab revealed that patients harboring a KRAS mutation did not benefit from treatment.
Thomas McFall, Edward Cooper Stites
doaj   +1 more source